Avidity Biosciences, Inc.·4

Jan 23, 5:34 PM ET

Hughes Steven George 4

Research Summary

AI-generated summary

Updated

Avidity (RNA) CMO Steven G. Hughes Sells Shares

What Happened

  • Steven G. Hughes, Chief Medical Officer of Avidity Biosciences (RNA), sold a total of 4,895 shares on January 21, 2026. The sales were in two lots: 2,017 shares and 2,878 shares, each at $72.45 per share, totaling approximately $354,643. These were sales (not purchases).

Key Details

  • Transaction date and price: January 21, 2026 — 2,017 shares @ $72.45 ($146,132) and 2,878 shares @ $72.45 ($208,511).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnote: The shares were sold to cover tax withholding obligations arising from RSUs that vested on January 20, 2026. The sale was a mandatory "sell-to-cover" under the issuer's equity plan and not a discretionary trade by the reporting person. The reporting person executed an instruction letter for automatic sale intended to satisfy the affirmative defense conditions of Rule 10b5-1 (per footnote F1).
  • Filing timeliness: Report filed January 23, 2026 for trades on January 21, 2026 — appears to be timely.

Context

  • These were routine sell-to-cover transactions to satisfy tax withholding on vested restricted stock units, a common administrative transaction that does not necessarily signal a change in the insider’s view of the company. The filing notes the use of an automatic instruction/10b5-1-related procedure to execute the sales.